On March 14, 2024, Regulus Therapeutics Inc. closed the transaction. The company issued 45,108,667 shares of the Company's common stock at a purchase price of $1.60 per share for the gross proceeds of $72,173,867.2 and 173,915 non-voting class A-6 convertible preferred stock at a purchase price of $160 per share for the gross proceeds of $27,826,400 for the aggregate gross proceeds of approximately $100,000,000. Stelios Papadopoulos is a Purchaser under the Purchase Agreement and purchased 250,000 shares of Common Stock.

The transaction included participation from returning investor, Growth Equity Opportunities V, LLC.